IGC Pharma Reports Second Quarter Fiscal 2024 Results
IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the second fiscal quarter of 2024 ended September 30, 2023 (Q2 FY2024).
- IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the second fiscal quarter of 2024 ended September 30, 2023 (Q2 FY2024).
- Revenue in Q2 FY2024 increased 44% to approximately $291,000 compared to the same quarter in FY2023 at roughly $202,000.
- In the first six months of FY2024, revenue doubled to about $846,000 from about $414,000 compared to the prior year’s six-month period.
- The Company continues to drive progress with ten sites in the United States and Canada, currently conducting the trial.